Savaria (Sweden) owns 95.4 per cent of the shares in Handicare following completion of the Offer
THIS PRESS RELEASE IS NOT AN OFFER, WHETHER DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SOUTH AFRICA, SWITZERLAND OR THE UNITED STATES OR IN ANY OTHER JURISDICTION WHERE SUCH OFFER PURSUANT TO LEGISLATION AND REGULATIONS IN SUCH RELEVANT JURISDICTION WOULD BE PROHIBITED BY APPLICABLE LAW. SHAREHOLDERS NOT RESIDENT IN SWEDEN WHO WISH TO ACCEPT THE OFFER (AS DEFINED BELOW) MUST MAKE INQUIRIES CONCERNING APPLICABLE LEGISLATION AND POSSIBLE TAX CONSEQUENCES. SHAREHOLDERS SHOULD REFER TO THE OFFER RESTRICTIONS INCLUDED IN THE SECTION TITLED “IMPORTANT INFORMATION” AT THE END OF THIS PRESS RELEASE AND IN THE OFFER DOCUMENT PUBLISHED ON SAVARIA (SWEDEN)’S WEBSITE (WWW.NORDIC-OFFER.COM).
STOCKHOLM, Sweden, March 19, 2021 (GLOBE NEWSWIRE) -- On 27 January 2021, Savaria (Sweden) AB1 (“Savaria (Sweden)”), a company wholly owned by Savaria Corporation2 (“Savaria”), announced a recommended cash offer to the shareholders of Handicare Group AB (“Handicare”) to tender all their shares in Handicare to Savaria (Sweden) at a final price of SEK 50 in cash per share (the “Offer”).
At the end of the initial acceptance period on 4 March 2021, Savaria (Sweden) announced that the Offer had been accepted by shareholders representing 56,118,445 shares in Handicare, corresponding to 95.2 per cent of the total number of shares and votes in Handicare. Since shareholders representing more than 90 per cent of the shares in Handicare had accepted the Offer, all conditions for completion of the Offer had been fulfilled. Accordingly, the Offer was declared unconditional in all respects and Savaria (Sweden) announced that it would complete the acquisition of the shares tendered in the Offer. Furthermore, Savaria (Sweden) announced that it had initiated compulsory redemption of the remaining shares in Handicare and that the acceptance period was extended until 18 March 2021 at 5:00 p.m. (CET). The board of directors of Handicare has since announced that it has resolved to apply for delisting of Handicare’s shares from Nasdaq Stockholm and that the last day of trading in Handicare’s shares will be 26 March 2021.
The Offer is now completed. At the end of the extended acceptance period on 18 March 2021, the Offer has been accepted by shareholders representing an additional 101,064 shares in Handicare, corresponding to approximately 0.2 per cent of the total number of shares and votes in Handicare. This entails that Savaria (Sweden) now owns a total of 56,219,509 shares in Handicare, corresponding to approximately 95.4 per cent of the total number of shares and votes in Handicare. Settlement of the shares tendered in the Offer during the extension of the acceptance period is expected to commence on or around 25 March 2021.
Pursuant to the obligation under the Nasdaq Stockholm takeover rules to procure fair treatment of participants in long-term incentive plans, Savaria (Sweden) has offered the participants in Handicare’s long-term incentive program 2019 to sell their warrants of series LTIP 2019 to Savaria (Sweden) at a price per warrant of SEK 5.02 as calculated using the so-called see-through value.
Information about the Offer
The offer document in Swedish and English and other information about the Offer is available on Savaria (Sweden)’s website (www.nordic-offer.com).
Chief Executive Officer
Chief Financial Officer
Vice President, Corporate Development
+1 (450) 254-0115
For administrative questions regarding the Offer, please contact your bank or the nominee registered as holder of your shares.
Savaria (Sweden) discloses the information provided herein pursuant to the Swedish Stock Market (Takeover Bids) Act and the Swedish Takeover Rules. The information was submitted for announcement at 2:00 p.m. (CET) on 19 March 2021.
This press release has been published in Swedish and English. In the event of any discrepancy in content between the two language versions, the Swedish version shall prevail.
The Offer is not being made, directly or indirectly, in or into Australia, Canada, Hong Kong, Japan, New Zealand, South Africa, Switzerland or the United States or in any other jurisdiction where such offer pursuant to legislation and regulations in such relevant jurisdiction would be prohibited by applicable law, by use of mail or any other communication means or instrumentality (including, without limitation, facsimile transmission, electronic mail, telex, telephone and the Internet) of interstate or foreign commerce, or of any facility of national securities exchange or other trading venue, of Australia, Canada, Hong Kong, Japan, New Zealand, South Africa, Switzerland or the United States, and the Offer cannot be accepted by any such use or by such means, instrumentality or facility of, in or from, Australia, Canada, Hong Kong, Japan, New Zealand, South Africa, Switzerland or the United States. Accordingly, this press release or any documentation relating to the Offer are not being and should not be sent, mailed or otherwise distributed or forwarded in or into Australia, Canada, Hong Kong, Japan, New Zealand, South Africa, Switzerland or the United States.
This press release is not being, and must not be, sent to shareholders with registered addresses in Australia, Canada, Hong Kong, Japan, New Zealand, South Africa, Switzerland or the United States. Banks, brokers, dealers and other nominees holding shares for persons in Australia, Canada, Hong Kong, Japan, New Zealand, South Africa, Switzerland or the United States must not forward this press release or any other document received in connection with the Offer to such persons. For purposes of this section, “United States” refers to the United States of America (its territories and possessions, any state of the United States and the District of Columbia).
The Offer and the information and documents contained in this press release are not being made and have not been approved by an authorized person for the purposes of section 21 of the UK Financial Services and Markets Act 2000 (the “FSMA”). Accordingly, the information and documents contained in this press release are not being distributed to, and must not be passed on to, the general public in the United Kingdom. The communication of the information and documents contained in this press release is exempt from the restriction on financial promotions under section 21 of the FSMA on the basis that it is a communication by or on behalf of a body corporate which relates to a transaction to acquire day to day control of the affairs of a body corporate; or to acquire 50 per cent or more of the voting shares in a body corporate, within article 62 of the UK Financial Services and Markets Act 2000 (Financial Promotion) Order 2005.
Statements in this press release relating to future status or circumstances, including statements regarding future performance, growth and other trend projections and other benefits of the Offer, are forward-looking statements. These statements may generally, but not always, be identified by the use of words such as “anticipates”, “intends”, “expects”, “believes”, or similar expressions. By their nature, forward-looking statements involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. There can be no assurance that actual results will not differ materially from those expressed or implied by these forward-looking statements due to many factors, many of which are outside the control of Savaria (Sweden). Any such forward-looking statements speak only as of the date on which they are made and Savaria (Sweden) has no obligation (and undertakes no such obligation) to update or revise any of them, whether as a result of new information, future events or otherwise, except for in accordance with applicable laws and regulations.
1 A newly established company under name change from Goldcup 26098 AB.
2 A corporation organised and existing under the laws of the Province of Alberta, Canada, with Canadian registration number 1161491460, having its registered office at 4350 Highway 13, Laval, Québec H7R 6E9 Canada and listed on the Toronto Stock Exchange (TSX:SIS).
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
Active Biotech and NeoTX announce FDA Clearance of IND for Phase II Clinical Trial of Naptumomab19.4.2021 08:30:00 CEST | Press release
Phase IIa trial in non-small cell lung cancer expected to begin enrollment in the US in the second half of 2021 Lund Sweden, April 19, 2021 - Active Biotech AB (publ) (NASDAQ STOCKHOLM: ACTI) and NeoTX today announced that they have received clearance from the U.S. Food and Drug Administration (FDA) for the Investigational New Drug (IND) application of the tumor targeted superantigen naptumomab estafenatox (Naptumomab). The Phase IIa open label trial will evaluate naptumomab in combination with docetaxel in 35 patients with checkpoint inhibitor pretreated, advanced or metastatic non-small cell lung cancer. The primary endpoint is objective response rate as measured by RECIST 1.1 criteria. The trial will also evaluate safety, duration of response, progression free survival, pharmacokinetics and pharmacodynamics. Naptumomab treatment regimens have demonstrated preliminary safety and anti-tumor activity in early-stage clinical trials in solid tumors. Naptumomab binds a genetically enginee
Active Biotech och NeoTX tillkännager IND-godkännande från FDA för klinisk fas II-studie med naptumomab19.4.2021 08:30:00 CEST | Pressemelding
En fas IIa-studie i icke-småcellig lungcancer förväntas starta rekrytering i USA under andra halvåret 2021 Lund, 19 april 2021 - Active Biotech AB (publ) (NASDAQ STOCKHOLM: ACTI) och NeoTX tillkännager idag att man har erhållit godkännande av en Investigational New Drug-ansökan (IND) från amerikanska läkemedelsverket Food and Drug Administration (FDA) för det tumörriktade superantigenet naptumomab estafenatox (naptumomab). Den öppna fas IIa-studien kommer att utvärdera naptumomab i kombination med docetaxel i 35 patienter med avancerad eller metastaserad icke-småcellig lungcancer och som är förbehandlade med checkpoint-hämmare. Det primära målet är objektiv responsfrekvens mätt med RECIST 1.1-kriterier. Studien kommer också att utvärdera säkerhet, responsduration, progressionsfri överlevnad, farmakokinetik och farmakodynamik. Behandlingsregimer för naptumomab har visat preliminär säkerhet och antitumöraktivitet i tidiga kliniska studier i patienter med solida tumörer. Naptumomab binder
Immunicum Announces Presentations at Upcoming Scientific Conferences in April and May19.4.2021 08:00:00 CEST | Press release
Press Release 19 April 2021 Immunicum Announces Presentations at Upcoming Scientific Conferences in April and May Immunicum AB (publ) today announced that it will participate and deliver multiple presentations featuring its proprietary Phase II clinical candidates, immune primer ilixadencel and cancer relapse vaccine DCP-001, at the following upcoming scientific conferences: Neoantigen Summit Europe, April 20 – 22, 2021 Alex Karlsson-Parra, Chief Scientific Officer at Immunicum, will make an oral presentation on “Harnessing the immune-priming function of allogeneic dendritic cells in neoantigen-based vaccines”, on Wednesday, April 21st at 2:45 pm CET / 8:45 am ET. Cancer Immunotherapy (CIMT) Annual Meeting, May 10 – 12, 2021. Alex Karlsson-Parra will deliver an oral presentation on “Combining intratumoral administration of inflammatory allogeneic DCs with systemic anti-CTLA-4 treatment leads to tumor eradication and is associated with peripheral expansion of CD8+ effector cells with a
Intervest starts construction works at Herentals Green Logistics19.4.2021 08:00:00 CEST | Press release
#TeamIntervest gives concrete shape to a sustainable cluster of 45.000 m² of offices and logistics. Attachment Development project Herentals
Immunicum tillkännager presentationer vid kommande vetenskapliga möten i april och maj19.4.2021 08:00:00 CEST | Pressemelding
Pressrelease 19 april 2021 Immunicum tillkännager presentationer vid kommande vetenskapliga möten i april och maj Immunicum AB (publ) meddelade idag att bolaget kommer att delta och göra ett flertal presentioner gällande sina två program i klinisk fas II-utveckling, immunprimern ilixadencel och canceråterfallsvaccinet DCP-001 vid nedanstående vetenskapliga möten: Neoantigen Summit Europe, 20 – 22 april, 2021 Alex Karlsson-Parra, Chief Scientific Officer, Immunicum håller ett anförande på temat ” “Harnessing the immune-priming function of allogeneic dendritic cells in neoantigen-based vaccines”, onsdagen den 21 april kl. 14.45 CET/8.45 ET. Cancer Immunotherapy (CIMT) Annual Meeting, 10-12 maj, 2021 Alex Karlsson-Parra, Chief Scientific Officer, Immunicum håller ett anförande på temat “Combining intratumoral administration of inflammatory allogeneic DCs with systemic anti-CTLA-4 treatment leads to tumor eradication and is associated with peripheral expansion of CD8+ effector cells with a
ABN AMRO accepted settlement offer in the anti-money laundering investigation in the Netherlands19.4.2021 07:30:00 CEST | Press release
ABN AMRO accepted settlement offer in the anti-money laundering investigation in the Netherlands Today ABN AMRO Bank N.V. (ABN AMRO) announced that it has accepted a settlement offer from the Dutch Public Prosecution Service (DPPS) in connection with the previously announced investigation by the DPPS into ABN AMRO's compliance with its obligations under the Dutch Anti-Money Laundering and Counter Terrorism Financing Act (Wet ter voorkoming van witwassenen financiering van terrorisme, AML/CTF Act) between 2014 and 2020. As part of this settlement, ABN AMRO will pay EUR 480 million. ABN AMRO fully cooperated with the DPPS throughout the investigation. Based on the investigation, the DPPS identified serious shortcomings in ABN AMRO's processes to combat money laundering in the Netherlands, such as the client acceptance, transaction monitoring and client exit processes (the so-called 'Client Life Cycle' processes) in the period between 2014 and 2020, as a result of which, in certain instan
Nyxoah Announces Submission of Draft Registration Statement For Proposed Public Listing in the United States19.4.2021 07:02:32 CEST | Press release
REGULATED INFORMATION INSIDE INFORMATION Nyxoah Announces Submission of Draft Registration Statement For Proposed Public Listing in the United States Mont-Saint-Guibert, Belgium – 19 April 2021 – Nyxoah SA (Euronext Brussels: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that it has confidentially submitted a draft Registration Statement on Form F-1 to the Securities and Exchange Commission (the "SEC") relating to the proposed public offering of its ordinary shares in the United States. The number of ordinary shares to be offered and the price for the proposed offering have not yet been determined. The public offering is expected to take place after the SEC completes its review process, subject to market and other conditions. This announcement is being made pursuant to, and in accordance with, Rule 135 under the Securities Act of 1933, as am